FXYD5 promotes the growth of glioblastoma by targeting the PI3K/AKT/ACSL4 signaling axis
Bang Wang, Yong Qin, Hang Cheng, Yibin Zeng, Lianglei Jiang, Xuebin Hu · 2026
Read FXYD5 promotes the growth of glioblastoma by targeting the PI3K/AKT/ACSL4 signaling axis by Bang Wang, Yong Qin, Hang Cheng, Yibin Zeng, Lianglei Jiang, Xuebin Hu (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13613038.txt.
Description
Bang Wang and five colleagues published a 2026 study of a gene called FXYD5 in glioblastoma, the most malignant primary brain tumor. Treatment options for glioblastoma are limited and survival is poor. FXYD5 has been reported as dysregulated in several cancers, making it a candidate target for precision medicine.
Database analyses showed FXYD5 is markedly upregulated in glioblastoma, and higher levels correlate with worse patient prognosis. The team then manipulated the gene in two glioblastoma cell lines, LN229 and U251, reducing it in some cells and boosting it in others. Cell growth and death assays tracked the effects. The gene acts through the PI3K/AKT/ACSL4 signaling axis, a growth pathway. Blocking FXYD5 could become a new therapeutic angle.
Catalog record
| CREATOR | Bang Wang, Yong Qin, Hang Cheng, Yibin Zeng, Lianglei Jiang, Xuebin Hu |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 48 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |